Search Results
Your search for ,iII matches 9602 pages
Showing 6751 - 6800Adding Idelalisib to Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
As reported by Zelenetz et al in The Lancet Oncology, an interim analysis of a phase III trial has shown the superiority of adding the phosphoinositide-3-kinase δ inhibitor idelalisib (Zydelig) to bendamustine/rituximab (Rituxan) in patients with relapsed or refractory chronic lymphocytic...
Retinoic Acid and Arsenic Trioxide vs Retinoic Acid and Chemotherapy in APL
As reported in the Journal of Clinical Oncology by Platzbecker et al, the final results of the Italian-German phase III APL0406 trial indicate that the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO [Trisenox]) is associated with better outcomes than standard ATRA plus...
Clinical Trials Actively Recruiting Patients With Cancer-Related Pain
Phase I Study Title: Qigong Mind-Body Exercise for Persistent Post-Surgical Pain in Breast Cancer Survivors: A Pilot Study Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Spaulding...
Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction
The multihumoral manifestations of neuroendocrine tumors include diarrhea, cutaneous flushing, wheezing, and right-sided valvular heart disease.1 Serotonin, a biogenic amine and product of tryptophan metabolism,2 mediates several of these symptoms.3,4 Diarrhea is a cardinal and often disabling...
Telotristat Ethyl Reduces Frequency of Bowel Movements in Patients With Metastatic Neuroendocrine Tumors and Carcinoid Syndrome
In the phase III TELESTAR trial reported in the Journal of Clinical Oncology by Matthew H. Kulke, MD, of Dana-Farber Cancer Institute, and colleagues, telotristat ethyl, an investigational tryptophan hydroxylase inhibitor, significantly reduced the frequency of bowel movements in patients with...
ASCEND-4 Study Shows 45% Reduction in Risk of Disease Progression for NSCLC Patients on First-Line Ceritinib
Compared to chemotherapy, the use of first-line ceritinib (Zykadia) resulted in a statistically significant and clinically meaningful improvement in median progression-free survival, with an estimated 45% reduction in disease progression risk, as well as significant improvements in quality of...
FDA Accepts Two sBLAs for Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer
On February 3, the U.S. Food and Drug Administration (FDA) accepted for review two supplemental Biologics License Applications (sBLAs) for pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial cancer. Specifically, the application for first-line use was accepted and...
Increased Risk of Cardiac Events With High Heart Dose in High-Dose Thoracic Radiotherapy
In a single-center pooled analysis reported in the Journal of Clinical Oncology, Wang et al found that a higher dose of radiation to the heart was associated with an increased risk of cardiac events in patients receiving high-dose radiation therapy for stage III non–small cell lung cancer...
Accelerated Partial-Breast vs Whole-Breast Irradiation After Breast-Conserving Surgery
As reported in The Lancet Oncology by Polgár et al, 5-year late side effects and cosmetic results were similar with accelerated partial-breast irradiation (APBI) with interstitial brachytherapy vs whole-breast irradiation (WBI) after breast-conserving surgery for low-risk invasive and in...
Adding Antiandrogen Therapy to Radiation Therapy in Recurrent Prostate Cancer
As reported in The New England Journal of Medicine by Shipley et al in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial showed that the addition of antiandrogen therapy with bicalutamide to radiation therapy significantly improves overall ...
Study Finds Durvalumab of Benefit in Advanced and Metastatic Non–Small Cell Lung Cancer
Durvalumab was active and led to long-lasting response in a cohort of heavily pretreated patients with epidermal growth factor receptor/anaplastic lymphoma kinase (EGFR/ALK) wild-type locally advanced and metastatic non–small cell lung cancer (NSCLC), particularly among patients whose tumors...
Early Success Reported With Two New Agents for High-Risk Myelodysplastic Syndromes
At the 2016 American Society for Hematology (ASH) Annual Meeting & Exposition, researchers reported early success with two new experimental agents for high-risk myelodysplastic syndromes—enasidenib (also known as AG-221), a potent oral inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme,...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in several different types of non-Hodgkin lymphomas (NHLs), including mantle cell lymphoma and marginal zone lymphoma. For...
Studies Advance the Use of PD-1 Blockade in Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma is one of the malignancies most susceptible to treatment with monoclonal antibodies targeting the programmed cell death protein (PD-1). Nivolumab (Opdivo) has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed/refractory...
Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD
Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you are a patient with symptoms, such as a cough from lung metastases, and I give you a combination...
Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers
A randomized phase II study in women with metastatic breast cancer who have mutations in BRCA1 or BRCA2 evaluated the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to combination chemotherapy. The trial did not meet its primary endpoint.1 Hyo Sook Han, MD, of Moffitt...
Adjuvant Letrozole vs Anastrozole in Hormone Receptor–Positive Node-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Smith et al, the final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopausal women with hormone receptor–positive node-positive early breast...
Tumor-Infiltrating Lymphocytes Prognostic in the Metastatic and Neoadjuvant Breast Cancer Settings
Studies presented at the 2016 San Antonio Breast Cancer Symposium added to growing evidence that tumor-infiltrating lymphocytes are important prognostic factors in breast cancer. One investigation evaluated their impact in advanced HER2-positive breast cancer, finding a linear relationship between...
Nivolumab, as Salvage, Improves Overall Survival in Gastric Cancer
Gastric cancer can apparently be added to the growing list of malignancies for which drugs targeting the programmed cell death protein 1 (PD‑1) receptor are effective, according to the results of the phase III ONO-4538 investigation conducted in Asia and presented at the 2017 Gastrointestinal...
Phase III Trial Finds First-Line Ceritinib Improves PFS vs Platinum-Based Chemotherapy in ALK-Rearranged NSCLC
In a phase III trial (ASCEND-4) reported in The Lancet, Soria et al found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in first-line treatment of advanced ALK-rearranged non–small cell lung cancer (NSCLC). Ceritinib is a next-generation selective...
Postmenopausal Normal-Weight Women With Poor Metabolic Health May Have Higher Risk for Colorectal Cancer
Few studies have explored the association between metabolic phenotype and colorectal cancer incidence in normal-weight individuals. Now, a study comparing the risk of colorectal cancer in normal-weight postmenopausal women with a metabolically unhealthy phenotype vs those with a metabolically...
Study Finds Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Resected Pancreatic Cancer
In the European phase III ESPAC-4 trial reported in The Lancet, Neoptolemos et al found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients with resected pancreatic cancer. Study Details In the open-label trial, 730 patients from 92 hospitals in...
Diagnosis and Management of AML in Adults: 2017 European LeukemiaNet Recommendations From an International Expert Panel
An international panel of experts has released updated evidence-based and expert opinion–based recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults. The recommendations were issued by the European LeukemiaNet (ELN) and published by Döhner et al in...
Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy
In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...
New Molecular-Based Prognostic Model for Glioblastoma in Temozolomide Era
In a study reported in JAMA Oncology, Bell et al derived a molecular-based recursive partitioning analysis model for overall survival in glioblastoma multiforme in the temozolomide era with the aim of refining existing clinically based models. Study Details The study involved analysis of 452...
Androgen Maintenance in Elderly Patients With AML
The addition of norethandrolone as maintenance therapy improved survival in patients aged ≥ 60 years with acute myeloid leukemia (AML), according to a French phase III trial reported in the Journal of Clinical Oncology by Pigneux et al. Norbert Ifrah, MD, of CHU d’Angers, France, is the...
Addition of Palifosfamide to Doxorubicin in Metastatic Soft-Tissue Sarcoma
In the phase III PICASSO III trial reported in the Journal of Clinical Oncology, Christopher W. Ryan, MD, of Oregon Health & Science University, and colleagues found that adding palifosfamide to doxorubicin did not prolong progression-free survival among patients with metastatic soft-tissue...
Second-Line Ramucirumab in Advanced HCC
In an exploratory analysis of the REACH trial in advanced hepatocellular carcinoma reported in JAMA Oncology, Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues found a borderline survival benefit of second-line ramucirumab (Cyramza)...
Clinical Trials Actively Recruiting Patients With Bladder Cancer
Phase I Study Title: Ethacrynic Acid Elimination in Nonmuscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: University of Kansas Medical Center Purpose: To provide quantitative...
Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?
Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not responded to corticosteroids, but this may be about to change. Ibrutinib (Imbruvica) achieved...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in follicular lymphoma. For full details of these study abstracts, visit http://www.bloodjournal.org/content/128/22....
Vanderbilt Study to Explore Lymphedema Self-Care for Head and Neck Cancer Survivors
Vanderbilt University School of Nursing Assistant Professor Jie Deng, PhD, RN, has been awarded a $789,000 research scholar grant by the American Cancer Society to develop and test a self-care program for head and neck cancer survivors diagnosed with secondary lymphedema/fibrosis....
PARP Inhibitor Niraparib Yields ‘Unprecedented’ Results in Ovarian Cancer in Phase III Trial
The first phase III trial of an inhibitor of poly (ADP-ribose) polymerase (PARP) yielded unprecedented results in treating ovarian cancer. The trial was presented at the European Society for Medical Oncology (ESMO) in Copenhagen, Denmark, and electronically reported concurrently in The New England ...
Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III trial (ENGOT-OV16/NOVA) reported at the 2016 ESMO (European Society for Medical Oncology) Congress and in The New England Journal of Medicine by Mansoor R. Mirza, MD, of the Rigshospitalet–Copenhagen University Hospital, and colleagues, maintenance therapy with the PARP (poly...
Masanori Terashima, MD, PhD, on Gastric Cancer: Results of the JCOG1001 Trial
Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).
Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
Nivolumab Improves Overall Survival in Recurrent Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Robert L. Ferris, MD, PhD, of the University of Pittsburgh Medical Center and Cancer Institute, and colleagues found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with...
Antiretroviral Agent Makes Strong Showing in Refractory Multiple Myeloma
An antiretroviral drug that is used for human immunodeficiency virus (HIV) demonstrated strong activity when combined with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma in a small multicenter phase II study presented at the 2016 American Society of Hematology (ASH)...
CAR T-Cell Therapy KTE-C19 Appears Successful in Aggressive B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pivotal phase II ZUMA-1 trial, the first multicenter trial of the experimental CAR T-cell therapy...
Expert Point of View: Philip McCarthy, MD
The ASCO Post asked Philip McCarthy, MD, Professor of Oncology and Internal Medicine at Roswell Park Cancer, Buffalo, and Director of the Blood and Marrow Transplant Center there, to comment on these study findings. He first addressed the need to study earlier intervention for smoldering ...
Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer Symposium....
Pertuzumab, Trastuzumab, Plus Aromatase Inhibitor Beneficial in Metastatic Breast Cancer
In the phase II PERTAIN study of locally advanced or metastatic hormone receptor–positive, HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab (Herceptin) and an aromatase inhibitor in the first-line setting significantly improved progression-free ...
2017 GI Cancers Symposium: Nivolumab Demonstrated Efficacy and Improved Survival in Patients With Previously Treated Advanced Gastric Cancer
Results of the ONO-4538-12 trial demonstrated that nivolumab (Opdivo) significantly reduced the risk of death by 37% (hazard ratio [HR] = 0.63; P < .0001) in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current ...
Risk Factors for Estrogen Receptor–Positive and –Negative Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Kerlikowske et al identified risk factors for estrogen receptor–positive and –negative breast cancer using data from the Breast Cancer Surveillance Consortium. The analysis included 1,279,443 women, aged 35 to 74...
Novel Antibody May Reduce Debilitating Symptoms in Patients With Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Hickish et al found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite outcome of stabilizing/improving lean body mass and debilitating...
Osimertinib Significantly Improves Survival for Patients With Non–Small Cell Lung Cancer
For patients with epidermal growth factor receptor (EGFR) T790M–positive non–small cell lung cancer (NSCLC), osimertinib (Tagrisso) demonstrated clinically superior efficacy over pemetrexed (Alimta) plus a platinum agent, with a 70% reduction in the risk of disease progression, according to the...
Lenalidomide Maintenance Extends Progression-Free Survival in CLL
Lenalidomide (Revlimid), a cornerstone of therapy for multiple myeloma in the modern era, is making headway as maintenance therapy in chronic lymphocytic leukemia (CLL). Separate phase III studies presented at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition showed...
Lu-177 Dotatate Improves Progression-Free Survival in Midgut Neuroendocrine Tumors
In a phase III trial (NETTER-1) reported in The New England Journal of Medicine, Strosberg et al found that the addition of the targeted radiotherapeutic agent lutetium Lu-177 dotatate to octreotide long-acting repeatable (LAR) (Sandostatin LAR) significantly improved progression-free...
2017 GI Cancers Symposium: Physical Activity May Be Linked to Longer Survival in Advanced Colorectal Cancer
A new analysis of the CALGB 80405 (Alliance) trial suggests that people with metastatic colorectal cancer who are more physically active fare better than those who are less active. In a large clinical trial, patients who at the time of starting chemotherapy reported engaging in physical activity...
2017 GI Cancers Symposium: PET Scans Can Inform and Improve Treatment for Patients With Esophageal Cancer
Findings from a federally funded clinical trial—CALGB 80803 (Alliance)—point to a new way to improve the outlook for patients with esophageal cancer: using positron-emission tomography (PET) scans to assess tumor response to initial chemotherapy may allow doctors to tailor further...
